Loading...
Market
What major industry award will AUCATZYL® (obe-cel) win in 2025?
2
Resolution / Starting Odds
Best New Drug • 25%
Innovation in Oncology • 25%
No major award • 25%
Other • 25%
Industry award announcements
Story
Autolus Therapeutics Gains FDA Approval for AUCATZYL® (obe-cel) CAR-T Therapy in Leukemia
Nov 11, 2024, 12:14 PM
Autolus Therapeutics has received FDA approval for its CAR-T therapy, AUCATZYL® (obecabtagene autoleucel – obe-cel), for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This marks the first product approval for the UK-based biotech company. Autolus stock rose 9.9% pre-market following the announcement.
View original story
Similar markets
Nobel Prize in Medicine • 25%
Breakthrough Prize in Life Sciences • 25%
No major awards • 25%
Other recognition • 25%
CES Innovation Award • 25%
Green IT Award • 25%
TechCrunch Disrupt Award • 25%
Other • 25%
Nobel Prize • 25%
Lasker Award • 25%
Breakthrough Prize • 25%
No award • 25%
Yes • 50%
No • 50%
Another cancer therapy • 25%
A non-cancer therapy • 25%
No new approvals • 25%
Other • 25%
Cybersecurity Award • 25%
Innovation Award • 25%
Leadership Award • 25%
No recognition • 25%
Yes • 50%
No • 50%
Chronic Disease Management • 25%
Mental Health • 25%
Telemedicine • 25%
Other • 25%
Best AI Technology • 25%
Innovation in Software Development • 25%
Breakthrough of the Year • 25%
Other • 25%
Phase 2 Completion • 25%
Partnership/Acquisition • 25%
FDA Approval • 25%
Other • 25%
Nobel Prize • 25%
Lasker Award • 25%
Royal Society Medal • 25%
Other major award • 25%